Enhanced S-Cone Syndrome: Spectrum of Clinical, Imaging, Electrophysiologic, and Genetic Findings in a Retrospective Case Series of 56 Patients.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
02 2021
Historique:
received: 09 05 2020
revised: 06 07 2020
accepted: 09 07 2020
pubmed: 18 7 2020
medline: 16 11 2021
entrez: 18 7 2020
Statut: ppublish

Résumé

To describe the detailed phenotype, long-term clinical course, clinical variability, and genotype of patients with enhanced S-cone syndrome (ESCS). Retrospective case series. Fifty-six patients with ESCS. Clinical history, examination, imaging, and electrophysiologic findings of 56 patients (age range, 1-75 years) diagnosed with ESCS were reviewed. Diagnosis was established by molecular confirmation of disease-causing variants in the NR2E3 gene (n = 38) or by diagnostic full-field electroretinography findings (n = 18). Age at onset of visual symptoms, best-corrected visual acuity (BCVA), quantitative age-related electrophysiologic decline, and imaging findings. Mean age at onset of visual symptoms was 4.0 years, and median age at presentation was 20.5 years, with mean follow-up interval being 6.1 years. Six patients were assessed once. Disease-causing variants in NR2E3 were identified in 38 patients. Mean BCVA of the better-seeing eye was 0.32 logarithm of the minimum angle of resolution (logMAR) at baseline and 0.39 logMAR at follow-up. In most eyes (76% [76/100]), BCVA remained stable, with a mean BCVA change of 0.07 logMAR during follow-up. Nyctalopia was the most common initial symptom, reported in 92.9% of patients (52/56). Clinical findings were highly variable and included foveomacular schisis (41.1% [26/56]), yellow-white dots (57.1% [32/56]), nummular pigmentation (85.7% [48/56]), torpedo-like lesions (10.7% [6/56]), and circumferential subretinal fibrosis (7.1% [4/56]). Macular and peripheral patterns of autofluorescence were classified as (1) minimal change, (2) hypoautofluorescent (mild diffuse, moderate speckled, moderate diffuse, or advanced), or (3) hyperautofluorescent flecks. One patient showed undetectable electroretinography findings; quantification of main electroretinography components in all other patients revealed amplitude and peak time variability but with pathognomonic electroretinography features. The main electroretinography components showed evidence of age-related worsening over 6.7 decades, at a rate indistinguishable from that seen in unaffected control participants. Eighteen sequence variants in NR2E3 were identified, including 4 novel missense changes. Enhanced S-cone syndrome has a highly variable phenotype with relative clinical and imaging stability over time. Most electroretinography findings have pathognomonic features, but quantitative assessment reveals variability and a normal mean rate of age-related decline, consistent with largely nonprogressive peripheral retinal dysfunction.

Identifiants

pubmed: 32679203
pii: S2468-6530(20)30286-4
doi: 10.1016/j.oret.2020.07.008
pmc: PMC7861019
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-214

Subventions

Organisme : Wellcome Trust
ID : 099173/Z/12/Z
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Références

Br J Ophthalmol. 2007 Mar;91(3):394-6
pubmed: 17322467
Ophthalmologe. 2001 Mar;98(3):285-93
pubmed: 11320818
Clin Exp Ophthalmol. 2016 Jan-Feb;44(1):69-71
pubmed: 26154701
Nat Genet. 1999 Oct;23(2):217-21
pubmed: 10508521
Nat Genet. 2001 Dec;29(4):447-52
pubmed: 11694879
BMJ Case Rep. 2009;2009:
pubmed: 21686439
Prog Retin Eye Res. 2011 Jul;30(4):258-74
pubmed: 21477661
PLoS Genet. 2005 Aug;1(2):e11
pubmed: 16110338
Am J Ophthalmol. 1991 Apr 15;111(4):446-53
pubmed: 2012146
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Br J Ophthalmol. 2005 Aug;89(8):1065-6
pubmed: 16024868
JAMA Ophthalmol. 2013 Oct;131(10):1324-30
pubmed: 23989059
Invest Ophthalmol Vis Sci. 2016 Oct 01;57(13):5361-5371
pubmed: 27732723
JAMA Ophthalmol. 2014 Nov;132(11):1341-9
pubmed: 25079116
Case Rep Ophthalmol. 2018 Dec 21;9(3):510-515
pubmed: 30687072
Vis Neurosci. 2006 Nov-Dec;23(6):917-29
pubmed: 17266784
Exp Eye Res. 2010 Aug;91(2):116-7
pubmed: 20450910
J Neurosci. 2005 Jan 5;25(1):118-29
pubmed: 15634773
Invest Ophthalmol Vis Sci. 2008 May;49(5):2082-93
pubmed: 18436841
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):201-8
pubmed: 20725840
Doc Ophthalmol. 2020 Apr;140(2):95-101
pubmed: 31749034
Bioinformatics. 2015 Aug 15;31(16):2745-7
pubmed: 25851949
Am J Hum Genet. 2007 Jul;81(1):147-57
pubmed: 17564971
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):963-76
pubmed: 24425859
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Mol Vis. 2007 Oct 17;13:1970-5
pubmed: 17982421
Doc Ophthalmol. 2006 Nov;113(3):213-5
pubmed: 17109156
Electrophoresis. 2009 Jun;30 Suppl 1:S162-73
pubmed: 19517507
Hum Genet. 2000 Sep;107(3):276-84
pubmed: 11071390
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Hum Mutat. 2009 Mar;30(3):342-51
pubmed: 19006237
Brain Res. 2008 Oct 21;1236:16-29
pubmed: 18294621
Mol Vis. 2009 Oct 24;15:2174-84
pubmed: 19898638
Indian J Ophthalmol. 2019 Apr;67(4):523-529
pubmed: 30900587
Genes (Basel). 2018 Jan 30;9(2):
pubmed: 29385733
Invest Ophthalmol Vis Sci. 1990 May;31(5):827-38
pubmed: 2335450
Br J Ophthalmol. 2009 Sep;93(9):1234-40
pubmed: 19429590
Am J Ophthalmol. 1990 Aug 15;110(2):124-34
pubmed: 2378376
Doc Ophthalmol. 2016 Oct;133(2):139-143
pubmed: 27424008
PLoS One. 2013 Sep 12;8(9):e74359
pubmed: 24069298
PLoS One. 2012;7(10):e46688
pubmed: 23056405
Exp Eye Res. 2009 Sep;89(3):365-72
pubmed: 19379737
Ophthalmology. 2017 Jun;124(6):884-895
pubmed: 28341475
Annu Rev Vis Sci. 2015 Nov 24;1:211-234
pubmed: 28532380
PLoS One. 2011 Mar 08;6(3):e17494
pubmed: 21408158
J Refract Surg. 1997 Jul-Aug;13(4):388-91
pubmed: 9268940
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFe1-6
pubmed: 27116662
PLoS One. 2014 Jan 31;9(1):e87942
pubmed: 24498227
Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319
pubmed: 27899672
Mol Vis. 2003 Jan 24;9:14-7
pubmed: 12552256
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Hum Mutat. 2004 Nov;24(5):439
pubmed: 15459973
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Retin Cases Brief Rep. 2019 Fall;13(4):295-299
pubmed: 28541266
Hum Mutat. 2015 Jun;36(6):599-610
pubmed: 25703721
PLoS One. 2009 Oct 12;4(10):e7379
pubmed: 19823680
Vision Res. 1996 Nov;36(22):3711-22
pubmed: 8977001
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):473-8
pubmed: 11773633
Adv Exp Med Biol. 2018;1085:153-156
pubmed: 30578501
Vision Res. 1995 May;35(10):1473-81
pubmed: 7645276
Doc Ophthalmol. 1988 Jun;69(2):167-74
pubmed: 3168720
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):266-70
pubmed: 1729696
Br J Ophthalmol. 2004 Sep;88(9):1180-5
pubmed: 15317712
Genomics. 1997 Oct 15;45(2):395-401
pubmed: 9344665
Arch Ophthalmol. 2003 Sep;121(9):1316-23
pubmed: 12963616
Dev Genes Evol. 2008 Aug;218(8):439-44
pubmed: 18592265
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4814-9
pubmed: 10220376
Hum Mol Genet. 2001 Aug 1;10(16):1619-26
pubmed: 11487564
Ophthalmology. 2005 Dec;112(12):2115
pubmed: 16225923
Br J Ophthalmol. 1990 Dec;74(12):739-42
pubmed: 2275937
Hum Mutat. 2009 Nov;30(11):1475-85
pubmed: 19718767
Doc Ophthalmol. 2013 Feb;126(1):1-7
pubmed: 23073702
Nat Genet. 2000 Feb;24(2):127-31
pubmed: 10655056
Am J Ophthalmol. 2007 Jul;144(1):157-9
pubmed: 17601449
Br J Ophthalmol. 2008 Feb;92(2):299-300
pubmed: 18227217

Auteurs

Emanuel R de Carvalho (ER)

Moorfields Eye Hospital, London, United Kingdom; Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Anthony G Robson (AG)

Moorfields Eye Hospital, London, United Kingdom; Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Gavin Arno (G)

Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom.

Camiel J F Boon (CJF)

Department of Ophthalmology, Amsterdam University Medical Centers, Amsterdam, The Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.

Andrew A Webster (AA)

Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom.

Michel Michaelides (M)

Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom. Electronic address: michel.michaelides@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH